Study summary

Wiping out eosinophils did not improve swallowing

Benralizumab trial · Phase 3 · Published June 2024, New England Journal of Medicine

What was tested

Benralizumab, an antibody that removes eosinophils from the blood and tissue, against placebo in eosinophilic esophagitis.

What they found

Benralizumab removed eosinophils from the esophagus in almost everyone, far more than placebo.
Swallowing symptoms did not improve more than with placebo.

What it means

Showed eosinophils are not the whole story. Treatments that block upstream signals (IL-13, TSLP) may work better.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.